Evaluation of the surface based measures to discriminate progressive supranuclear palsy from corticobasal syndrome
Objective: To evaluate structural gray matter (GM) changes tested by surface-based measures of cortical thickness (CTh), surface area (SA) and volume (VOL), in order to…In vivo evaluation of tau pathologies in patient with progressive supranuclear palsy and healthy subjects with [11C]PBB3-PET
Objective: This study was aimed at evaluating pathological tau accumulations in the brains of patients with progressive supranuclear palsy (PSP) and young and old healthy…Tau dysfunction in the basal ganglia of a mouse model of tauopathy related to PSP
Objective: Determine motor coordination and neurochemical phenotypes in the basal ganglia of mice lacking the Tau protein or expressing an abnormal content of Tau isoforms.…“Words untold”
Objective: To highlight the salient clinical and pathologic features of primary progressive apraxia of speech through a clinical case presentation. Background: Apraxia of speech is…Dorsal simultanagnosia as a cortical sign in the tauopathy spectrum
Objective: Clinical characterization of a tauopathy spectrum patient. Background: In recent years phenotypic overlap has been demonstrated between patients with progressive supranuclear palsy (PSP) pathology…FYN expression is associated with regulatory region genetic variation
Objective: The hypothesis of this investigation was that FYN expression and promoter activity are significantly influenced according to genetic content. The objective of this investigation…Clinical predictors of progressive supranuclear palsy (PSP) pathology in PSP syndrome
Objective: To elucidate specific clinical features of progressive supranuclear palsy (PSP) pathology in PSP syndrome. Background: PSP syndrome (PSPS) is the clinical hallmark of PSP;…Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3beta activity
Objective: To identify disease-modifying therapy for LRRK2-G2019S parkinsonism. Background: Leucine-rich repeat kinase 2 (LRRK2) is the most common genetic cause of Parkinson's disease (PD) without…Defining the pathology underlying cortico-basal syndrome: A European study
Objective: To understand how clinical and biological features can help us define and explain the varying pathology that underlies corticobasal syndrome (CBS). Background: Corticobasal degeneration…Low cerebrospinal fluid 3,4-dihydroxyphenylacetic acid and 3,4-dihydroxyphenylglycol levels are biomarkers of Parkinsonian disorders, including PSP
Objective: To assess whether Progressive Sopranuclear Palsy (PSP) patients show, in CSF an alteration of catecholamine metabolites. Background: It was reported previously that, consistent with…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.